GEBZIAS Trademark

Trademark Overview


On Friday, January 27, 2023, a trademark application was filed for GEBZIAS with the United States Patent and Trademark Office. The USPTO has given the GEBZIAS trademark a serial number of 97771219. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Wednesday, June 19, 2024. This trademark is owned by Eli Lilly and Company. The GEBZIAS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, hearing loss, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative co...
gebzias

General Information


Serial Number97771219
Word MarkGEBZIAS
Filing DateFriday, January 27, 2023
Status730 - FIRST EXTENSION - GRANTED
Status DateWednesday, June 19, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 14, 2023

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, hearing loss, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, February 15, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Wednesday, February 15, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, January 31, 2023NEW APPLICATION ENTERED
Wednesday, October 4, 2023ASSIGNED TO EXAMINER
Wednesday, October 11, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, October 25, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 14, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 9, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, November 14, 2023PUBLISHED FOR OPPOSITION
Wednesday, June 19, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, June 19, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, June 19, 2024SOU EXTENSION 1 FILED
Wednesday, June 19, 2024SOU EXTENSION 1 GRANTED